A 66-year-old retired accountant is evaluated in the clinic for a 12-month history of progressive memory impairment. His husband reports that the patient frequently forgets recent conversations, struggles to manage their household finances, and occasionally gets lost in familiar neighborhoods. His past medical history is significant for well-controlled hypertension and hyperlipidemia. Vital signs are within normal limits, and a general physical examination shows no acute abnormalities. The physician suspects a major neurocognitive disorder and plans a comprehensive diagnostic evaluation. Arrange the following diagnostic and evaluative steps in the most appropriate, standard chronological sequence for the workup of this patient.
- 1Administration of a standardized bedside cognitive assessment tool (e.g., Montreal Cognitive Assessment)
- 2Laboratory testing (e.g., thyroid-stimulating hormone, vitamin B12) to evaluate for reversible systemic etiologies
- 3Structural neuroimaging of the brain (e.g., non-contrast magnetic resonance imaging)
- 4Functional neuroimaging (e.g., fluorodeoxyglucose-positron emission tomography) or cerebrospinal fluid biomarker analysis
Answer
The standard diagnostic sequence begins with objective cognitive screening, followed by laboratory evaluation for reversible causes, structural neuroimaging to assess for cerebrovascular or space-occupying lesions, and finally, advanced functional imaging or biomarker testing if the diagnosis remains unclear.
The evaluation of suspected major neurocognitive disorder is a standardized, step-wise process designed to minimize unnecessary testing while identifying reversible causes. It begins with establishing the presence and severity of cognitive decline using validated bedside screening tools. Once cognitive impairment is objectively confirmed, the next step is to rule out common, reversible metabolic and systemic causes using routine laboratory tests. Following this, structural neuroimaging (preferably an MRI) is obtained to rule out structural lesions (e.g., subdural hematoma, tumors) and cerebrovascular disease, as well as to identify supportive anatomical changes (e.g., hippocampal atrophy). Finally, if the diagnosis remains uncertain and differentiating between specific neurodegenerative diseases is necessary for management, advanced diagnostics such as FDG-PET or cerebrospinal fluid biomarkers are indicated.
Step-by-Step Solution
Key Concept
Sequential Diagnostic Evaluation of Major Neurocognitive Disorders
Estimated Time:1m 15s